NCT05915546已完成1 期
A Phase 1, Open-label Trial to Evaluate the Effect of Food on the Pharmacokinetics of Emraclidine in Healthy Adult Participants
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- Maximum Observed Plasma Concentration (Cmax) of Emraclidine and its Metabolite CV-0000364
研究概览
简要总结
The primary purpose of this study is to evaluate the effect of food (a high-fat meal) on the pharmacokinetics of emraclidine and metabolite CV-0000364 following single oral dose administration in healthy adult participants.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male and female (both women of childbearing and nonchildbearing potential) participants, ages 18 to 55 years, at the time of signing the informed consent form (ICF).
- •Sexually active women of childbearing potential must agree to use an acceptable birth control method, during the trial and for 7 days after the last dose. Acceptable birth control methods that result in a failure rate of more than 1% per year include the following:
- •Progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action
- •Male or female condom with or without spermicide
- •Cap, diaphragm, or sponge with spermicide
- •Body mass index of 17.5 to 32.0 kilograms per square meter (kg/m^2), inclusive, and total body weight >45 kg (110 pounds [lb]) at Screening.
- •Healthy as determined by medical evaluation, including medical and psychiatric history, physical and neurological examinations, ECG, vital sign measurements, and laboratory test results, as evaluated by the investigator.
- •Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the full protocol.
- •Ability, in the opinion of the investigator, to understand the nature of the trial and comply with protocol requirements, including the prescribed dosage regimens, scheduled visits, laboratory tests, and other trial procedures.
排除标准
- •Current or past history of significant cardiovascular, pulmonary, gastrointestinal, renal, hepatic, metabolic, genitourinary, endocrine (including diabetes mellitus, thyroid disorders), malignancy, hematological, immunological, neurological, or psychiatric disease that, in the opinion of the investigator or medical monitor, could compromise either participant safety or the results of the trial.
- •"Yes" responses for any of the following items on the C-SSRS (within the individual's lifetime):
- •Suicidal Ideation Item 3 (Active Suicidal Ideation With Any Methods [Not Plan] Without Intent to Act)
- •Suicidal Ideation Item 4 (Active Suicidal Ideation With Some Intent to Act, Without Specific Plan)
- •Suicidal Ideation Item 5 (Active Suicidal Ideation With Specific Plan and Intent)
- •Any of the Suicidal Behavior items (Actual Attempt, Interrupted Attempt, Aborted Attempt, or Preparatory Acts/Behavior) "Yes" responses for any of the following items on the C-SSRS (within past 12 months):
- •Suicidal Ideation Item 1 (Wish to be Dead)
- •Suicidal Ideation Item 2 (Non-Specific Active Suicidal Thoughts) Serious risk of suicide in the opinion of the investigator is also exclusionary
- •Any condition or surgery that could possibly affect drug absorption, including, but not limited to, bowel resections, bariatric weight loss surgery/procedures, gastrectomy, and cholecystectomy.
- •Use of any prescription and over-the-counter medications from 28 days prior to first dose of Investigational Medical Product or likely to require concomitant therapy (e.g., prescription and over-the counter medications, herbal medications, vitamins, and supplements) during the trial, with the exception of acetaminophen (maximum total daily dose of 2 g) and topical hydrocortisone as needed for treatment of an Adverse Event(AE). Vaccinations or boosters within 7 days of planned dosing or while on trial are prohibited.
- •Positive result for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen, hepatitis B core antibody, or hepatitis C antibody with detectable viral ribonucleic acid (RNA) levels at Screening.
- •Positive drug screen or a positive test for alcohol at Screening or Baseline Visits.
- •Female participants who are pregnant, breastfeeding, or planning to become pregnant during IMP treatment or within 7 days after the last dose of IMP. Women of childbearing potential must have a negative serum pregnancy test result at the Screening Visit and a negative urine pregnancy test result at baseline.
- •Any of the following clinical laboratory test results at the Screening Visit (as assessed by the central laboratory) and at Check-in (Day -1; as assessed by the local laboratory), and confirmed by a single repeat measurement, if deemed necessary:
- •aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥2.0 × upper limit normal (ULN)
- •Total bilirubin >1.5 × ULN. If Gilbert's syndrome is suspected, total bilirubin >1.5 × ULN is acceptable if the conjugated or direct bilirubin fraction is <20% of total bilirubin.
研究组 & 干预措施
Emraclidine (Fasted then Fed)
Experimental
Single oral dose of Emraclidine 15 mg tablet under fasted (without food) condition followed by fed condition in treatment period 1 and 2, respectively.
干预措施: Emraclidine (Drug)
Emraclidine (Fed then Fasted)
Experimental
Single oral dose of Emraclidine 15 mg tablet under fed condition followed by fasted (without food) condition in treatment period 1 and 2, respectively.
干预措施: Emraclidine (Drug)
结局指标
主要结局
Maximum Observed Plasma Concentration (Cmax) of Emraclidine and its Metabolite CV-0000364
时间窗: Pre-dose and at multiple timepoints up to Day 6
Time to Maximum Plasma Concentration (Tmax) of Emraclidine and its Metabolite CV-0000364
时间窗: Pre-dose and at multiple timepoints up to Day 6
Area Under the Plasma Concentration-time Curve from Time Zero to Last Specified Sampling Time (AUC0-t) of Emraclidine and its Metabolite CV-0000364
时间窗: Pre-dose and at multiple timepoints up to Day 6
Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf) of Emraclidine and its Metabolite CV-0000364
时间窗: Pre-dose and at multiple timepoints up to Day 6
次要结局
- Number of Participants With Clinically Significant Changes in Physical and Neurological Examination Results(Up to Day 13)
- Number of Participants With Clinically Significant Changes in Vital Sign Measurements(Up to Day 13)
- Number of Participants With Treatment-emergent Adverse Events (TEAEs)(Up to Day 13)
- Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Parameters(Up to Day 13)
- Number of Participants With Clinically Significant Changes in Laboratory Assessments(Up to Day 13)
- Changes in Suicidality Assessed Using the Columbia Suicide Severity Rating Scale (C-SSRS)(Up to Day 13)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Phase 1, Open-Label Study to Evaluate the Effect of a Low-Fat Meal and Multiple Doses of Ciprofloxacin on the Pharmacokinetics of Vorasidenib in Healthy SubjectsHealthy SubjectsNCT05843708Servier Bio-Innovation LLC64
已完成
1 期
A Study to Understand the Effect of Low-Fat and High-Fat Meals on the Medicine Called PF-07284890 in Healthy AdultsHealthy ParticipantsNCT05349864Pfizer12
已完成
1 期
A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168Anti-neutrophil Cytoplasmic Antibody-associated VasculitisNCT05988021Amgen16
已完成
1 期
Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HClSchizophrenia, Schizoaffective Disorder, or Schizophreniform DisorderNCT01074632Sumitomo Pharma America, Inc.26
已完成
1 期
A Clinical Study to Investigate the Potential Interactions Between Food and ACT-541468 and Between ACT-541468 and MidazolamHealthy SubjectsNCT03017495Idorsia Pharmaceuticals Ltd.20